Skip to content
  • Home
  • Technology
    • The platform
    • Artificial Intelligence
    • BioClick
    • Nobel Prize heritage
    • Biosolution phases
    • Scientific papers
    • Patents
  • Pipeline
    • Pipeline overview
    • NCT: Over-the-Counter
    • NCT: Pharma
    • Cannabinoids
    • Santalene
    • Become a partner
  • Investors
    • Stock information
    • News
    • Email signup
    • Investor Relation Contacts
    • Governance
    • SEC Filings
    • Video
  • About
    • Leadership team
    • History
    • Jobs
    • Policies
    • Contact
  • News
    • Latest news
    • Media coverage
    • Investor news
    • News archive
Homepage
Open navigation
  • Home
  • Technology
    • The platform
    • Artificial Intelligence
    • BioClick
    • Nobel Prize heritage
    • Biosolution phases
    • Scientific papers
    • Patents
  • Pipeline
    • Pipeline overview
    • NCT: Over-the-Counter
    • NCT: Pharma
    • Cannabinoids
    • Santalene
    • Become a partner
  • Investors
    • Stock information
    • News
    • Email signup
    • Investor Relation Contacts
    • Governance
    • SEC Filings
    • Video
  • About
    • Leadership team
    • History
    • Jobs
    • Policies
    • Contact
  • News
    • Latest news
    • Media coverage
    • Investor news
    • News archive

Posts in: press release (4)

ARCHIVE: Invizyne Technologies Announces Pricing of $15 Million Initial Public Offering
press releaseinvestorARCHIVE
ARCHIVE: Invizyne Technologies Announces Pricing of $15 Million Initial Public OfferingNovember 11, 2024
ARCHIVE: MDB Capital Announces Record Date and Expected Timing for Initial Public Offering for Invizyne Technologies
press releaseinvestorARCHIVE
ARCHIVE: MDB Capital Announces Record Date and Expected Timing for Initial Public Offering for Invizyne TechnologiesJuly 11, 2024
ARCHIVE: Invizyne Technologies Expands Leadership Team Ahead of Proposed Offering and Listing on Nasdaq
talentpress releaseARCHIVE
ARCHIVE: Invizyne Technologies Expands Leadership Team Ahead of Proposed Offering and Listing on NasdaqMay 7, 2024
ARCHIVE: Invizyne Technologies Announces Filing of Registration Statement for Proposed Offering and Listing on Nasdaq
press releaseinvestorARCHIVE
ARCHIVE: Invizyne Technologies Announces Filing of Registration Statement for Proposed Offering and Listing on NasdaqFebruary 12, 2024
ARCHIVE: Invizyne Selected by Shell GameChanger Accelerator Powered by NREL for Sixth Cohort
biofuelpress releaseARCHIVE
ARCHIVE: Invizyne Selected by Shell GameChanger Accelerator Powered by NREL for Sixth CohortOctober 17, 2023
Invizyne Awarded Additional $3.77 Million Grant from U.S. Department of Energy
biofuelpress release
Invizyne Awarded Additional $3.77 Million Grant from U.S. Department of EnergyOctober 11, 2023
Previous page
Page 4 of 4
Next page

eXoZymes Inc.

750 Royal Oaks Dr, st 106, 
Monrovia 91016, CA, USA

P: (626) 415-1488
E: info@exozymes.com

 

© eXoZymes Inc. [Nasdaq:EXOZ] unshackling enzymes since 2019 (formerly known as Invizyne Technologies)

logo mark